The Health Insurance Review and Assessment Service (HIRA) has established a performance assessment plant for Qarziba and notified healthcare providers to submit documents.

Qarziba is a high-cost treatment for severe diseases. As of December 1, the drug was listed for reimbursement under the condition of patient performance-based Risk Sharing Agreements (RSA) for treatment effects monitoring and follow-up of reimbursement appropriateness.

According to sources on December 11, the number of drugs under the patient performance-based RSA increased to six, with the addition of Qarziba.

Patient performance-based RSA is a new payment system in which pharmaceutical companies' refund